Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 0.37 |
| ▸ | CNR1 | P21554 | 7/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19796609 | 0.92 | CNR2 (0.38) | CNR2CNR1CYP2C9ALDH1A1LMNA | |
| SCHEMBL19796585 | 0.92 | CNR2 (0.36) | CNR2CNR1CYP2C9ALDH1A1LMNA | |
| SCHEMBL19007881 | 0.91 | CNR2 (0.35) | CNR2CNR1CYP2C9ALDH1A1LMNA | |
| SCHEMBL19796997 | 0.89 | CNR2 (0.35) | CNR2CNR1CYP2C9ALDH1A1LMNA | |
| SCHEMBL19796990 | 0.88 | CNR2 (0.34) | CNR2CNR1CYP2C9ALDH1A1LMNA | |
| SCHEMBL19797002 | 0.88 | CYP3A4 (0.35) | CNR2CNR1CYP2C9 | |
| SCHEMBL19797003 | 0.87 | CNR2 (0.34) | CNR2CNR1CYP2C9TSHRRAB9A | |
| SCHEMBL19797020 | 0.87 | CNR2 (0.35) | CNR2CNR1CYP2C9TSHR | |
| SCHEMBL19804452 | 0.87 | FFAR4 (0.35) | CNR2CNR1CYP2C9 | |
| SCHEMBL19796996 | 0.87 | CYP2C9 (0.35) | CNR2CNR1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180023001-A1 | COMPOUND HAVING POLYMERIZABLE GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | SP1, C1S, AP3D1 | CNR2 1075/4885CNR1 320/4885CYP2C9 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.